Results: 5

1.
Figure 2

Figure 2. Multispecies alignment of protein sequences of key candidate genes in the metabolic pathway of ara-C. From: Genetic factors influencing cytarabine therapy.

The nonsynonymous coding polymorphisms are indicated on top of the alignment.

Jatinder K Lamba. Pharmacogenomics. ;10(10):1657-1674.
2.
Figure 5

Figure 5. Key functional and clinically significant SNPs studied in CDA. From: Genetic factors influencing cytarabine therapy.

AA: African–American; AML: Acute myeloid leukemia; CA: Caucasian–American; JA: Japanese; PK: Pharmacokinetics; TRM: Treatment-related mortality.

Jatinder K Lamba. Pharmacogenomics. ;10(10):1657-1674.
3.
Figure 1

Figure 1. Metabolic pathway of ara-C. From: Genetic factors influencing cytarabine therapy.

Key candidate genes involved in the metabolic activation of ara-C are shown. DCK and hENT1 are favorable for therapeutic efficacy of ara-C and other nucleoside analogs and CDA, DCTD and NT5C2 are not.
Ara-C: Cytarabine; CDA: Cytidine deaminase; DCK: Deoxycytidine kinase; DCTD: Deoxycytidylate deaminase; NT5C2: 5´nucleotidase.

Jatinder K Lamba. Pharmacogenomics. ;10(10):1657-1674.
4.
Figure 3

Figure 3. Key functional SNPs studied in SLC29A1. From: Genetic factors influencing cytarabine therapy.

The reference SNP numbers are provided where available and allele frequency is indicated in parenthesis beside the acronym for the respective ethnic group.
AA: African–American; AS: Asian; CA: Caucasian; EA: European–Americans; FTP: Fetoprotein transcription factor; JA: Japanese; LHR: Liver receptor homolog-1; ME: Mexican American; PA: Pacific Islander; TF: Transcription factor.

Jatinder K Lamba. Pharmacogenomics. ;10(10):1657-1674.
5.
Figure 4

Figure 4. Key functional SNPs studied in DCK. From: Genetic factors influencing cytarabine therapy.

The rs numbers are provided where available and allele frequency is indicated in parenthesis beside the acronym for the respective ethnic group.
A: HapMap YRI samples with African Ancestry; AA: African–American; AML: Acute myeloid leukemia; Ara-CTP: ara-cytidine-5´-triphosphate; CA: Caucasian–American; CH: Chinese; E: HapMap CEPH samples with European ancestry; HCA: Han Chinese–American; JA: Japanese; LD: Linkage disequilibrium; MA: Mexican–American; YRI: Yoruba people in Ibadan, Nigeria.

Jatinder K Lamba. Pharmacogenomics. ;10(10):1657-1674.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk